These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8140427)

  • 1. Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics.
    Bauer M; Brandstetter H; Turk D; Stürzebecher J; Bode W
    Semin Thromb Hemost; 1993; 19(4):352-60. PubMed ID: 8140427
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
    Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From natural to synthetic multisite thrombin inhibitors.
    Lombardi A; De Simone G; Galdiero S; Staiano N; Nastri F; Pavone V
    Biopolymers; 1999; 51(1):19-39. PubMed ID: 10380350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
    Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.
    Brandstetter H; Turk D; Hoeffken HW; Grosse D; Stürzebecher J; Martin PD; Edwards BF; Bode W
    J Mol Biol; 1992 Aug; 226(4):1085-99. PubMed ID: 1518046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Lewis BE; Bick RL; Walenga JM
    Semin Hematol; 1999 Jan; 36(1 Suppl 1):42-56. PubMed ID: 9930564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
    Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human alpha-thrombin.
    Jiang H; Chen K; Tang Y; Chen J; Li Q; Wang Q; Ji R
    J Med Chem; 1997 Sep; 40(19):3085-90. PubMed ID: 9301672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rational design of thrombin-directed antithrombotics.
    Fenton JW; Ni F; Witting JI; Brezniak DV; Andersen TT; Malik AB
    Adv Exp Med Biol; 1993; 340():1-13. PubMed ID: 8154327
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor binding to thrombin: x-ray crystallographic studies.
    Banner DW; Hadváry P
    Adv Exp Med Biol; 1993; 340():27-33. PubMed ID: 8154341
    [No Abstract]   [Full Text] [Related]  

  • 11. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
    De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
    Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and X-ray crystal structures of human thrombin with synthetic cyanopeptide-analogues.
    Radau G; Fokkens J
    Pharmazie; 2007 Feb; 62(2):83-8. PubMed ID: 17341023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
    Katakura S; Nagahara T; Hara T; Iwamoto M
    Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
    J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
    Deng JZ; McMasters DR; Rabbat PM; Williams PD; Coburn CA; Yan Y; Kuo LC; Lewis SD; Lucas BJ; Krueger JA; Strulovici B; Vacca JP; Lyle TA; Burgey CS
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4411-6. PubMed ID: 16137886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.
    Dementiev A; Petitou M; Herbert JM; Gettins PG
    Nat Struct Mol Biol; 2004 Sep; 11(9):863-7. PubMed ID: 15311268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of novel types of thrombin inhibitors based on modified D-Phe-Pro-Arg sequences.
    Claeson G; Elgendy S; Cheng L; Chino N; Goodwin CA; Scully MF; Deadman J
    Adv Exp Med Biol; 1993; 340():83-9. PubMed ID: 8154346
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure-based understanding of ligand affinity using human thrombin as a model system.
    Nienaber VL; Mersinger LJ; Kettner CA
    Biochemistry; 1996 Jul; 35(30):9690-9. PubMed ID: 8703940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient synthesis of an enantiopure beta-lactam as an advanced precursor of thrombin and tryptase inhibitors.
    Annunziata R; Benaglia M; Cinquini M; Cozzi F; Maggioni F; Puglisi A
    J Org Chem; 2003 Apr; 68(7):2952-5. PubMed ID: 12662075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.